Q-omics provides the consensus-scored KRT38 profile across patient tissues and cancer cell-line models. KRT38 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KRT38 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, KRT38 RNA expression shows 6,902 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, HNSC, and THYM as cancer lineages where KRT38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT38 survival associations across molecular data types. KRT38 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT38 RNA expression–survival associations across cancer types. High KRT38 expression shows unfavorable associations in BLCA, KIRC, UVM, ACC and KICH, but favorable associations in PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for KRT38 RNA expression.
This table summarizes KRT38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT38 shows lower tumor expression in HNSC and higher tumor expression in COAD, LUSC, READ, UCEC and BRCA. The HNSC box plot shows higher KRT38 RNA expression in normal versus tumor tissue (log2 FC = −0.117, t-test p = .010).
This table shows molecular features associated with KRT38 in patient tissues and cancer cell lines. In patient samples, KRT38 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
